nodes	percent_of_prediction	percent_of_DWPC	metapath
Amlexanox—PDE4D—prostate cancer	0.626	1	CbGaD
Amlexanox—IL3—bone marrow—prostate cancer	0.0071	0.0831	CbGeAlD
Amlexanox—S100A13—prostate gland—prostate cancer	0.00654	0.0765	CbGeAlD
Amlexanox—S100A12—prostate gland—prostate cancer	0.00645	0.0755	CbGeAlD
Amlexanox—S100A13—epithelium—prostate cancer	0.00481	0.0562	CbGeAlD
Amlexanox—S100A12—epithelium—prostate cancer	0.00474	0.0555	CbGeAlD
Amlexanox—S100A13—renal system—prostate cancer	0.00446	0.0522	CbGeAlD
Amlexanox—IL3—lymph node—prostate cancer	0.0044	0.0515	CbGeAlD
Amlexanox—PDE4D—prostate gland—prostate cancer	0.00431	0.0504	CbGeAlD
Amlexanox—FGF1—prostate gland—prostate cancer	0.00403	0.0471	CbGeAlD
Amlexanox—PDE4A—prostate gland—prostate cancer	0.00381	0.0446	CbGeAlD
Amlexanox—S100A12—bone marrow—prostate cancer	0.00333	0.0389	CbGeAlD
Amlexanox—FGF1—epithelium—prostate cancer	0.00296	0.0346	CbGeAlD
Amlexanox—S100A13—testis—prostate cancer	0.00288	0.0337	CbGeAlD
Amlexanox—S100A12—testis—prostate cancer	0.00284	0.0333	CbGeAlD
Amlexanox—Oropharyngeal pain—Cabazitaxel—prostate cancer	0.00275	0.0433	CcSEcCtD
Amlexanox—FGF1—renal system—prostate cancer	0.00275	0.0321	CbGeAlD
Amlexanox—PDE4B—prostate gland—prostate cancer	0.00227	0.0266	CbGeAlD
Amlexanox—Liver function test abnormal—Estramustine—prostate cancer	0.00225	0.0353	CcSEcCtD
Amlexanox—S100A13—lymph node—prostate cancer	0.00209	0.0244	CbGeAlD
Amlexanox—S100A12—lymph node—prostate cancer	0.00206	0.0241	CbGeAlD
Amlexanox—PDE4D—testis—prostate cancer	0.0019	0.0222	CbGeAlD
Amlexanox—FGF1—testis—prostate cancer	0.00177	0.0208	CbGeAlD
Amlexanox—PDE4A—testis—prostate cancer	0.00168	0.0196	CbGeAlD
Amlexanox—PDE4B—urethra—prostate cancer	0.00152	0.0178	CbGeAlD
Amlexanox—Liver function test abnormal—Bicalutamide—prostate cancer	0.00144	0.0226	CcSEcCtD
Amlexanox—S100A13—Estriol—Estramustine—prostate cancer	0.00142	0.271	CbGdCrCtD
Amlexanox—PDE4D—lymph node—prostate cancer	0.00138	0.0161	CbGeAlD
Amlexanox—FGF1—lymph node—prostate cancer	0.00129	0.015	CbGeAlD
Amlexanox—PDE4A—lymph node—prostate cancer	0.00122	0.0142	CbGeAlD
Amlexanox—PDE4B—bone marrow—prostate cancer	0.00117	0.0137	CbGeAlD
Amlexanox—S100A13—Estriol—Estrone—prostate cancer	0.00113	0.216	CbGdCrCtD
Amlexanox—Aphthous stomatitis—Epirubicin—prostate cancer	0.0011	0.0173	CcSEcCtD
Amlexanox—Throat sore—Docetaxel—prostate cancer	0.00106	0.0166	CcSEcCtD
Amlexanox—Oropharyngeal discomfort—Docetaxel—prostate cancer	0.00105	0.0165	CcSEcCtD
Amlexanox—Throat sore—Capecitabine—prostate cancer	0.00103	0.0161	CcSEcCtD
Amlexanox—Oropharyngeal discomfort—Capecitabine—prostate cancer	0.00102	0.016	CcSEcCtD
Amlexanox—Aphthous stomatitis—Doxorubicin—prostate cancer	0.00102	0.016	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Abiraterone—prostate cancer	0.001	0.0158	CcSEcCtD
Amlexanox—PDE4B—testis—prostate cancer	0.001	0.0117	CbGeAlD
Amlexanox—S100A13—Estriol—Conjugated Estrogens—prostate cancer	0.000992	0.19	CbGdCrCtD
Amlexanox—Nervous system disorder—Estradiol valerate/Dienogest—prostate cancer	0.000979	0.0154	CcSEcCtD
Amlexanox—Pain—Estrone—prostate cancer	0.000978	0.0154	CcSEcCtD
Amlexanox—Paraesthesia—Nilutamide—prostate cancer	0.000954	0.015	CcSEcCtD
Amlexanox—Nervous system disorder—Degarelix—prostate cancer	0.00093	0.0146	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Nilutamide—prostate cancer	0.000917	0.0144	CcSEcCtD
Amlexanox—Pain—Nilutamide—prostate cancer	0.000908	0.0143	CcSEcCtD
Amlexanox—Nervous system disorder—Cabazitaxel—prostate cancer	0.000876	0.0138	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Estradiol valerate/Dienogest—prostate cancer	0.000862	0.0135	CcSEcCtD
Amlexanox—S100A13—Estriol—Estradiol—prostate cancer	0.000854	0.163	CbGdCrCtD
Amlexanox—Pain—Estradiol valerate/Dienogest—prostate cancer	0.000853	0.0134	CcSEcCtD
Amlexanox—Oropharyngeal pain—Docetaxel—prostate cancer	0.000839	0.0132	CcSEcCtD
Amlexanox—S100A13—Estriol—Ethinyl Estradiol—prostate cancer	0.000833	0.16	CbGdCrCtD
Amlexanox—Mouth ulceration—Etoposide—prostate cancer	0.00083	0.013	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Degarelix—prostate cancer	0.000819	0.0129	CcSEcCtD
Amlexanox—Oropharyngeal pain—Capecitabine—prostate cancer	0.000813	0.0128	CcSEcCtD
Amlexanox—Pain—Degarelix—prostate cancer	0.000811	0.0127	CcSEcCtD
Amlexanox—Paraesthesia—Cabazitaxel—prostate cancer	0.000803	0.0126	CcSEcCtD
Amlexanox—Liver function test abnormal—Estradiol—prostate cancer	0.000794	0.0125	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Cabazitaxel—prostate cancer	0.000772	0.0121	CcSEcCtD
Amlexanox—Pain—Cabazitaxel—prostate cancer	0.000764	0.012	CcSEcCtD
Amlexanox—Nervous system disorder—Bicalutamide—prostate cancer	0.000752	0.0118	CcSEcCtD
Amlexanox—Headache—Estramustine—prostate cancer	0.00075	0.0118	CcSEcCtD
Amlexanox—PDE4B—lymph node—prostate cancer	0.000725	0.00849	CbGeAlD
Amlexanox—Headache—Estrone—prostate cancer	0.000716	0.0113	CcSEcCtD
Amlexanox—Nausea—Estramustine—prostate cancer	0.000711	0.0112	CcSEcCtD
Amlexanox—Paraesthesia—Bicalutamide—prostate cancer	0.000688	0.0108	CcSEcCtD
Amlexanox—Nausea—Estrone—prostate cancer	0.000679	0.0107	CcSEcCtD
Amlexanox—Mouth ulceration—Capecitabine—prostate cancer	0.000668	0.0105	CcSEcCtD
Amlexanox—Headache—Nilutamide—prostate cancer	0.000665	0.0105	CcSEcCtD
Amlexanox—Headache—Flutamide—prostate cancer	0.000662	0.0104	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Bicalutamide—prostate cancer	0.000662	0.0104	CcSEcCtD
Amlexanox—Pain—Bicalutamide—prostate cancer	0.000656	0.0103	CcSEcCtD
Amlexanox—Nervous system disorder—Ethinyl Estradiol—prostate cancer	0.000636	0.00999	CcSEcCtD
Amlexanox—Nausea—Nilutamide—prostate cancer	0.000631	0.00991	CcSEcCtD
Amlexanox—Nausea—Flutamide—prostate cancer	0.000628	0.00987	CcSEcCtD
Amlexanox—Headache—Estradiol valerate/Dienogest—prostate cancer	0.000625	0.00982	CcSEcCtD
Amlexanox—Stomatitis—Mitoxantrone—prostate cancer	0.000602	0.00946	CcSEcCtD
Amlexanox—Headache—Degarelix—prostate cancer	0.000594	0.00934	CcSEcCtD
Amlexanox—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.000593	0.00931	CcSEcCtD
Amlexanox—Nausea—Degarelix—prostate cancer	0.000564	0.00886	CcSEcCtD
Amlexanox—Headache—Cabazitaxel—prostate cancer	0.00056	0.0088	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Ethinyl Estradiol—prostate cancer	0.00056	0.00879	CcSEcCtD
Amlexanox—Nausea—Cabazitaxel—prostate cancer	0.000531	0.00834	CcSEcCtD
Amlexanox—Nervous system disorder—Goserelin—prostate cancer	0.000523	0.00822	CcSEcCtD
Amlexanox—Nervous system disorder—Conjugated Estrogens—prostate cancer	0.000518	0.00814	CcSEcCtD
Amlexanox—Liver function test abnormal—Docetaxel—prostate cancer	0.000512	0.00804	CcSEcCtD
Amlexanox—Stomatitis—Etoposide—prostate cancer	0.000501	0.00787	CcSEcCtD
Amlexanox—Liver function test abnormal—Capecitabine—prostate cancer	0.000495	0.00778	CcSEcCtD
Amlexanox—Headache—Bicalutamide—prostate cancer	0.00048	0.00755	CcSEcCtD
Amlexanox—Paraesthesia—Goserelin—prostate cancer	0.000479	0.00753	CcSEcCtD
Amlexanox—Paraesthesia—Conjugated Estrogens—prostate cancer	0.000474	0.00745	CcSEcCtD
Amlexanox—Mouth ulceration—Epirubicin—prostate cancer	0.000466	0.00732	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	0.000456	0.00717	CcSEcCtD
Amlexanox—Pain—Goserelin—prostate cancer	0.000456	0.00717	CcSEcCtD
Amlexanox—Nausea—Bicalutamide—prostate cancer	0.000455	0.00716	CcSEcCtD
Amlexanox—Pain—Conjugated Estrogens—prostate cancer	0.000452	0.0071	CcSEcCtD
Amlexanox—Mouth ulceration—Doxorubicin—prostate cancer	0.000431	0.00677	CcSEcCtD
Amlexanox—Stomatitis—Docetaxel—prostate cancer	0.000416	0.00654	CcSEcCtD
Amlexanox—Nervous system disorder—Estradiol—prostate cancer	0.000415	0.00652	CcSEcCtD
Amlexanox—Headache—Ethinyl Estradiol—prostate cancer	0.000406	0.00638	CcSEcCtD
Amlexanox—Stomatitis—Capecitabine—prostate cancer	0.000403	0.00633	CcSEcCtD
Amlexanox—Nausea—Ethinyl Estradiol—prostate cancer	0.000385	0.00605	CcSEcCtD
Amlexanox—Paraesthesia—Estradiol—prostate cancer	0.00038	0.00597	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Estradiol—prostate cancer	0.000365	0.00574	CcSEcCtD
Amlexanox—Pain—Estradiol—prostate cancer	0.000362	0.00568	CcSEcCtD
Amlexanox—Paraesthesia—Mitoxantrone—prostate cancer	0.000354	0.00556	CcSEcCtD
Amlexanox—Liver function test abnormal—Epirubicin—prostate cancer	0.000345	0.00542	CcSEcCtD
Amlexanox—Pain—Mitoxantrone—prostate cancer	0.000337	0.00529	CcSEcCtD
Amlexanox—Headache—Goserelin—prostate cancer	0.000334	0.00525	CcSEcCtD
Amlexanox—Headache—Conjugated Estrogens—prostate cancer	0.000331	0.0052	CcSEcCtD
Amlexanox—Liver function test abnormal—Doxorubicin—prostate cancer	0.000319	0.00502	CcSEcCtD
Amlexanox—Nausea—Goserelin—prostate cancer	0.000317	0.00498	CcSEcCtD
Amlexanox—Nausea—Conjugated Estrogens—prostate cancer	0.000314	0.00493	CcSEcCtD
Amlexanox—Paraesthesia—Etoposide—prostate cancer	0.000294	0.00462	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Etoposide—prostate cancer	0.000283	0.00445	CcSEcCtD
Amlexanox—Stomatitis—Epirubicin—prostate cancer	0.000281	0.00441	CcSEcCtD
Amlexanox—Pain—Etoposide—prostate cancer	0.00028	0.0044	CcSEcCtD
Amlexanox—Nervous system disorder—Docetaxel—prostate cancer	0.000267	0.0042	CcSEcCtD
Amlexanox—Headache—Estradiol—prostate cancer	0.000265	0.00416	CcSEcCtD
Amlexanox—Stomatitis—Doxorubicin—prostate cancer	0.00026	0.00408	CcSEcCtD
Amlexanox—Nervous system disorder—Capecitabine—prostate cancer	0.000259	0.00406	CcSEcCtD
Amlexanox—Nausea—Estradiol—prostate cancer	0.000251	0.00395	CcSEcCtD
Amlexanox—Headache—Mitoxantrone—prostate cancer	0.000247	0.00388	CcSEcCtD
Amlexanox—Paraesthesia—Docetaxel—prostate cancer	0.000245	0.00384	CcSEcCtD
Amlexanox—Paraesthesia—Capecitabine—prostate cancer	0.000237	0.00372	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Docetaxel—prostate cancer	0.000235	0.00369	CcSEcCtD
Amlexanox—Nausea—Mitoxantrone—prostate cancer	0.000234	0.00368	CcSEcCtD
Amlexanox—Pain—Docetaxel—prostate cancer	0.000233	0.00366	CcSEcCtD
Amlexanox—Nervous system disorder—Prednisone—prostate cancer	0.00023	0.00362	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Capecitabine—prostate cancer	0.000228	0.00358	CcSEcCtD
Amlexanox—Pain—Capecitabine—prostate cancer	0.000225	0.00354	CcSEcCtD
Amlexanox—Paraesthesia—Prednisone—prostate cancer	0.000211	0.00331	CcSEcCtD
Amlexanox—Headache—Etoposide—prostate cancer	0.000205	0.00323	CcSEcCtD
Amlexanox—Nausea—Etoposide—prostate cancer	0.000195	0.00306	CcSEcCtD
Amlexanox—Nervous system disorder—Epirubicin—prostate cancer	0.00018	0.00283	CcSEcCtD
Amlexanox—Headache—Docetaxel—prostate cancer	0.000171	0.00268	CcSEcCtD
Amlexanox—Nervous system disorder—Doxorubicin—prostate cancer	0.000167	0.00262	CcSEcCtD
Amlexanox—Headache—Capecitabine—prostate cancer	0.000165	0.0026	CcSEcCtD
Amlexanox—Paraesthesia—Epirubicin—prostate cancer	0.000165	0.00259	CcSEcCtD
Amlexanox—Nausea—Docetaxel—prostate cancer	0.000162	0.00254	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Epirubicin—prostate cancer	0.000159	0.00249	CcSEcCtD
Amlexanox—Pain—Epirubicin—prostate cancer	0.000157	0.00247	CcSEcCtD
Amlexanox—Nausea—Capecitabine—prostate cancer	0.000157	0.00246	CcSEcCtD
Amlexanox—Paraesthesia—Doxorubicin—prostate cancer	0.000153	0.0024	CcSEcCtD
Amlexanox—Headache—Prednisone—prostate cancer	0.000147	0.00231	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Doxorubicin—prostate cancer	0.000147	0.00231	CcSEcCtD
Amlexanox—Pain—Doxorubicin—prostate cancer	0.000145	0.00228	CcSEcCtD
Amlexanox—Nausea—Prednisone—prostate cancer	0.00014	0.00219	CcSEcCtD
Amlexanox—Headache—Epirubicin—prostate cancer	0.000115	0.00181	CcSEcCtD
Amlexanox—Nausea—Epirubicin—prostate cancer	0.000109	0.00171	CcSEcCtD
Amlexanox—Headache—Doxorubicin—prostate cancer	0.000106	0.00167	CcSEcCtD
Amlexanox—Nausea—Doxorubicin—prostate cancer	0.000101	0.00159	CcSEcCtD
Amlexanox—PDE4D—Signaling Pathways—GSK3B—prostate cancer	8.82e-06	4.02e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—KDR—prostate cancer	8.78e-06	4e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—NOS3—prostate cancer	8.76e-06	3.99e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—APC—prostate cancer	8.75e-06	3.98e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3CG—prostate cancer	8.75e-06	3.98e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—INS—prostate cancer	8.7e-06	3.96e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—JAK2—prostate cancer	8.69e-06	3.96e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—EGF—prostate cancer	8.64e-06	3.94e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IRS1—prostate cancer	8.64e-06	3.94e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—HIF1A—prostate cancer	8.56e-06	3.9e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—ESR1—prostate cancer	8.56e-06	3.9e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CREBBP—prostate cancer	8.52e-06	3.88e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—JAK2—prostate cancer	8.51e-06	3.88e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—MDM2—prostate cancer	8.49e-06	3.87e-05	CbGpPWpGaD
Amlexanox—S100A12—Immune System—IL6—prostate cancer	8.45e-06	3.85e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IGF1—prostate cancer	8.41e-06	3.83e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—GSK3B—prostate cancer	8.39e-06	3.82e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—CDKN1B—prostate cancer	8.39e-06	3.82e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—KRAS—prostate cancer	8.38e-06	3.82e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—EGFR—prostate cancer	8.37e-06	3.81e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—ERBB2—prostate cancer	8.37e-06	3.81e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—LEP—prostate cancer	8.36e-06	3.81e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—BAD—prostate cancer	8.36e-06	3.81e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—PIK3CA—prostate cancer	8.35e-06	3.8e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MDM2—prostate cancer	8.31e-06	3.79e-05	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—IL6—prostate cancer	8.29e-06	3.78e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CAV1—prostate cancer	8.28e-06	3.77e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—INS—prostate cancer	8.28e-06	3.77e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—PIK3CB—prostate cancer	8.26e-06	3.76e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—IL2—prostate cancer	8.21e-06	3.74e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—ERBB2—prostate cancer	8.19e-06	3.73e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—KDR—prostate cancer	8.19e-06	3.73e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—PTGS2—prostate cancer	8.18e-06	3.73e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MAP2K1—prostate cancer	8.13e-06	3.7e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CREBBP—prostate cancer	8.11e-06	3.69e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CG—prostate cancer	8.09e-06	3.69e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—APC—prostate cancer	8.09e-06	3.69e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PIK3CB—prostate cancer	8.09e-06	3.68e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PIK3CD—prostate cancer	8.08e-06	3.68e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IGF1—prostate cancer	8.01e-06	3.65e-05	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—PIK3CA—prostate cancer	8e-06	3.64e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IRS1—prostate cancer	8e-06	3.64e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—EGF—prostate cancer	8e-06	3.64e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—SERPINE1—prostate cancer	7.99e-06	3.64e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—ESR1—prostate cancer	7.98e-06	3.64e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—EGFR—prostate cancer	7.97e-06	3.63e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—CTNNB1—prostate cancer	7.93e-06	3.61e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—KRAS—prostate cancer	7.91e-06	3.6e-05	CbGpPWpGaD
Amlexanox—S100A12—Immune System—AKT1—prostate cancer	7.79e-06	3.55e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—BAD—prostate cancer	7.79e-06	3.55e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CXCL8—prostate cancer	7.77e-06	3.54e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—GSK3B—prostate cancer	7.76e-06	3.54e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—CDKN1B—prostate cancer	7.75e-06	3.53e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—CDKN1A—prostate cancer	7.74e-06	3.53e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MAP2K1—prostate cancer	7.74e-06	3.53e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—FGF2—prostate cancer	7.73e-06	3.52e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—PTEN—prostate cancer	7.73e-06	3.52e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—PIK3CA—prostate cancer	7.69e-06	3.51e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3CD—prostate cancer	7.69e-06	3.5e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—INS—prostate cancer	7.66e-06	3.49e-05	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—AKT1—prostate cancer	7.65e-06	3.48e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—NOS3—prostate cancer	7.63e-06	3.47e-05	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—PIK3CA—prostate cancer	7.61e-06	3.47e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—SERPINE1—prostate cancer	7.6e-06	3.46e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CDKN1B—prostate cancer	7.59e-06	3.46e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—APC—prostate cancer	7.54e-06	3.44e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CG—prostate cancer	7.54e-06	3.44e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—KRAS—prostate cancer	7.53e-06	3.43e-05	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—AKT1—prostate cancer	7.51e-06	3.42e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CREBBP—prostate cancer	7.5e-06	3.42e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—EGF—prostate cancer	7.46e-06	3.4e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IRS1—prostate cancer	7.46e-06	3.4e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—TP53—prostate cancer	7.44e-06	3.39e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CASP3—prostate cancer	7.44e-06	3.39e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—IL2—prostate cancer	7.43e-06	3.38e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—JAK2—prostate cancer	7.41e-06	3.38e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IGF1—prostate cancer	7.41e-06	3.38e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—IL6—prostate cancer	7.39e-06	3.37e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—EGFR—prostate cancer	7.37e-06	3.36e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—EP300—prostate cancer	7.37e-06	3.36e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—FGF2—prostate cancer	7.36e-06	3.35e-05	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—AKT1—prostate cancer	7.34e-06	3.34e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—CTNNB1—prostate cancer	7.32e-06	3.33e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—PIK3CA—prostate cancer	7.26e-06	3.31e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—NOS3—prostate cancer	7.26e-06	3.31e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CCND1—prostate cancer	7.24e-06	3.3e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—GSK3B—prostate cancer	7.24e-06	3.3e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MDM2—prostate cancer	7.24e-06	3.3e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CTNNB1—prostate cancer	7.17e-06	3.27e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—SRC—prostate cancer	7.17e-06	3.26e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MAP2K1—prostate cancer	7.16e-06	3.26e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—CDKN1A—prostate cancer	7.15e-06	3.26e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—INS—prostate cancer	7.14e-06	3.25e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—PTEN—prostate cancer	7.13e-06	3.25e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—ERBB2—prostate cancer	7.13e-06	3.25e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CD—prostate cancer	7.11e-06	3.24e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—JAK2—prostate cancer	7.06e-06	3.21e-05	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—PIK3CA—prostate cancer	7.05e-06	3.21e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PIK3CB—prostate cancer	7.04e-06	3.21e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—SERPINE1—prostate cancer	7.04e-06	3.21e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MMP9—prostate cancer	7.03e-06	3.2e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CDKN1A—prostate cancer	7e-06	3.19e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CREBBP—prostate cancer	7e-06	3.19e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PTEN—prostate cancer	6.99e-06	3.18e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—KRAS—prostate cancer	6.96e-06	3.17e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—PIK3CA—prostate cancer	6.92e-06	3.15e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—STAT3—prostate cancer	6.91e-06	3.15e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IGF1—prostate cancer	6.91e-06	3.15e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MDM2—prostate cancer	6.89e-06	3.14e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—AKT1—prostate cancer	6.82e-06	3.11e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—IL6—prostate cancer	6.81e-06	3.1e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—FGF2—prostate cancer	6.81e-06	3.1e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—EP300—prostate cancer	6.8e-06	3.1e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—ERBB2—prostate cancer	6.79e-06	3.09e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CXCL8—prostate cancer	6.77e-06	3.08e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—NOS3—prostate cancer	6.72e-06	3.06e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3CB—prostate cancer	6.7e-06	3.05e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MAP2K1—prostate cancer	6.68e-06	3.04e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—EP300—prostate cancer	6.66e-06	3.04e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CD—prostate cancer	6.63e-06	3.02e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—SRC—prostate cancer	6.62e-06	3.01e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CDKN1B—prostate cancer	6.61e-06	3.01e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—SERPINE1—prostate cancer	6.56e-06	2.99e-05	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—AKT1—prostate cancer	6.54e-06	2.98e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—JAK2—prostate cancer	6.53e-06	2.97e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—SRC—prostate cancer	6.48e-06	2.95e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CASP3—prostate cancer	6.48e-06	2.95e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IL2—prostate cancer	6.47e-06	2.95e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CXCL8—prostate cancer	6.44e-06	2.93e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—IL6—prostate cancer	6.43e-06	2.93e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—PIK3CA—prostate cancer	6.4e-06	2.91e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—STAT3—prostate cancer	6.38e-06	2.91e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MDM2—prostate cancer	6.37e-06	2.9e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—FGF2—prostate cancer	6.35e-06	2.89e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—VEGFA—prostate cancer	6.31e-06	2.88e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CCND1—prostate cancer	6.3e-06	2.87e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CDKN1B—prostate cancer	6.29e-06	2.86e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—AKT1—prostate cancer	6.29e-06	2.86e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—ERBB2—prostate cancer	6.28e-06	2.86e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—EGFR—prostate cancer	6.28e-06	2.86e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—NOS3—prostate cancer	6.26e-06	2.85e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—STAT3—prostate cancer	6.25e-06	2.85e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CTNNB1—prostate cancer	6.24e-06	2.84e-05	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—AKT1—prostate cancer	6.22e-06	2.83e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CB—prostate cancer	6.2e-06	2.82e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CASP3—prostate cancer	6.16e-06	2.81e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IL2—prostate cancer	6.15e-06	2.8e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—IL6—prostate cancer	6.12e-06	2.79e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MMP9—prostate cancer	6.12e-06	2.79e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CDKN1A—prostate cancer	6.1e-06	2.78e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—JAK2—prostate cancer	6.09e-06	2.77e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PTEN—prostate cancer	6.08e-06	2.77e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CCND1—prostate cancer	6e-06	2.73e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CXCL8—prostate cancer	5.96e-06	2.71e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MDM2—prostate cancer	5.94e-06	2.71e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CTNNB1—prostate cancer	5.94e-06	2.71e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—AKT1—prostate cancer	5.93e-06	2.7e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—KRAS—prostate cancer	5.93e-06	2.7e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—MYC—prostate cancer	5.93e-06	2.7e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—TGFB1—prostate cancer	5.91e-06	2.69e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—ERBB2—prostate cancer	5.86e-06	2.67e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MMP9—prostate cancer	5.82e-06	2.65e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CDKN1B—prostate cancer	5.82e-06	2.65e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MYC—prostate cancer	5.81e-06	2.65e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CDKN1A—prostate cancer	5.8e-06	2.64e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—EP300—prostate cancer	5.8e-06	2.64e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—EGFR—prostate cancer	5.8e-06	2.64e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—TGFB1—prostate cancer	5.79e-06	2.64e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PTEN—prostate cancer	5.79e-06	2.64e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CB—prostate cancer	5.78e-06	2.63e-05	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—AKT1—prostate cancer	5.76e-06	2.62e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CASP3—prostate cancer	5.7e-06	2.6e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IL2—prostate cancer	5.69e-06	2.59e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—EGFR—prostate cancer	5.68e-06	2.59e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—IL6—prostate cancer	5.67e-06	2.58e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—AKT1—prostate cancer	5.65e-06	2.57e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—SRC—prostate cancer	5.64e-06	2.57e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CXCL8—prostate cancer	5.56e-06	2.53e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CCND1—prostate cancer	5.55e-06	2.53e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—EP300—prostate cancer	5.52e-06	2.52e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CTNNB1—prostate cancer	5.5e-06	2.5e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—VEGFA—prostate cancer	5.49e-06	2.5e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—KRAS—prostate cancer	5.48e-06	2.5e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—PIK3CA—prostate cancer	5.45e-06	2.48e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—STAT3—prostate cancer	5.44e-06	2.48e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CDKN1B—prostate cancer	5.43e-06	2.47e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MMP9—prostate cancer	5.39e-06	2.46e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CDKN1A—prostate cancer	5.37e-06	2.45e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—SRC—prostate cancer	5.37e-06	2.45e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—KRAS—prostate cancer	5.37e-06	2.44e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PTEN—prostate cancer	5.36e-06	2.44e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CASP3—prostate cancer	5.32e-06	2.42e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IL2—prostate cancer	5.31e-06	2.42e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—VEGFA—prostate cancer	5.23e-06	2.38e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—AKT1—prostate cancer	5.23e-06	2.38e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—STAT3—prostate cancer	5.18e-06	2.36e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CCND1—prostate cancer	5.18e-06	2.36e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CTNNB1—prostate cancer	5.13e-06	2.33e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—EP300—prostate cancer	5.11e-06	2.33e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MYC—prostate cancer	5.06e-06	2.3e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—TGFB1—prostate cancer	5.04e-06	2.3e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—PIK3CA—prostate cancer	5.03e-06	2.29e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MMP9—prostate cancer	5.03e-06	2.29e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CDKN1A—prostate cancer	5.01e-06	2.28e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PTEN—prostate cancer	5e-06	2.28e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—SRC—prostate cancer	4.97e-06	2.26e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—EGFR—prostate cancer	4.94e-06	2.25e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PIK3CA—prostate cancer	4.93e-06	2.25e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—VEGFA—prostate cancer	4.84e-06	2.2e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—IL6—prostate cancer	4.83e-06	2.2e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MYC—prostate cancer	4.81e-06	2.19e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—TGFB1—prostate cancer	4.8e-06	2.19e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—STAT3—prostate cancer	4.79e-06	2.18e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—TP53—prostate cancer	4.77e-06	2.17e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—EP300—prostate cancer	4.76e-06	2.17e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—EGFR—prostate cancer	4.71e-06	2.14e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—KRAS—prostate cancer	4.67e-06	2.13e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—SRC—prostate cancer	4.63e-06	2.11e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—VEGFA—prostate cancer	4.51e-06	2.06e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—STAT3—prostate cancer	4.47e-06	2.04e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—IL6—prostate cancer	4.46e-06	2.03e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—AKT1—prostate cancer	4.45e-06	2.03e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MYC—prostate cancer	4.45e-06	2.03e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—KRAS—prostate cancer	4.45e-06	2.03e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—TGFB1—prostate cancer	4.44e-06	2.02e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—IL6—prostate cancer	4.37e-06	1.99e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—EGFR—prostate cancer	4.36e-06	1.98e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PIK3CA—prostate cancer	4.29e-06	1.96e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—TP53—prostate cancer	4.15e-06	1.89e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MYC—prostate cancer	4.15e-06	1.89e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—TGFB1—prostate cancer	4.14e-06	1.89e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—KRAS—prostate cancer	4.11e-06	1.87e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—AKT1—prostate cancer	4.11e-06	1.87e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3CA—prostate cancer	4.09e-06	1.86e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—EGFR—prostate cancer	4.06e-06	1.85e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—AKT1—prostate cancer	4.03e-06	1.83e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—TP53—prostate cancer	3.95e-06	1.8e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—KRAS—prostate cancer	3.84e-06	1.75e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IL6—prostate cancer	3.8e-06	1.73e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CA—prostate cancer	3.78e-06	1.72e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—TP53—prostate cancer	3.66e-06	1.67e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IL6—prostate cancer	3.62e-06	1.65e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CA—prostate cancer	3.52e-06	1.61e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—AKT1—prostate cancer	3.51e-06	1.6e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—TP53—prostate cancer	3.41e-06	1.55e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IL6—prostate cancer	3.35e-06	1.52e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—AKT1—prostate cancer	3.34e-06	1.52e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IL6—prostate cancer	3.12e-06	1.42e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—AKT1—prostate cancer	3.09e-06	1.41e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—AKT1—prostate cancer	2.88e-06	1.31e-05	CbGpPWpGaD
